Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Characteristics and Outcomes of rrHL Treated with Brentuximab Vedotin in Thailand
TCTR20220722003Recruiting
- Sponsor
- Takeda
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by Takeda. Started Dec 2025; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on TCTR20220722003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220722003.